| 查看: 833 | 回复: 1 | ||
marineman至尊木虫 (知名作家)
爱八卦爱生活
|
[求助]
iPath2为何经常无法访问? 已有1人参与
|
|
http://pathways.embl.de 经常无法访问,可其他人都说可以。有时候上去了,输出结果图片也不成功。 Nucleic Acids Res. 2011 Jul;39(Web Server issue):W412-5. doi: 10.1093/nar/gkr313. Epub 2011 May 5. iPath2.0: interactive pathway explorer. Yamada T1, Letunic I, Okuda S, Kanehisa M, Bork P. Abstract iPath2.0 is a web-based tool (http://pathways.embl.de) for the visualization and analysis of cellular pathways. Its primary map summarizes the metabolism in biological systems as annotated to date. Nodes in the map correspond to various chemical compounds and edges represent series of enzymatic reactions. In two other maps, iPath2.0 provides an overview of secondary metabolite biosynthesis and a hand-picked selection of important regulatory pathways and other functional modules, allowing a more general overview of protein functions in a genome or metagenome. iPath2.0's main interface is an interactive Flash-based viewer, which allows users to easily navigate and explore the complex pathway maps. In addition to the default pre-computed overview maps, iPath offers several data mapping tools. Users can upload various types of data and completely customize all nodes and edges of iPath2.0's maps. These customized maps give users an intuitive overview of their own data, guiding the analysis of various genomics and metagenomics projects. |
» 猜你喜欢
PRMT5·MTA 抑制剂 MRTX1719 的科研应用
已经有0人回复
SW033291 科研使用解析:分子特征、储存与实验获取要点
已经有0人回复
化学工程及工业化学论文润色/翻译怎么收费?
已经有223人回复
泛 RAS 抑制新思路:大环肽拟似物如何同时牵住突变型与野生型 RAS?
已经有0人回复
TYK2/JAK1 双靶点工具化合物 Brepocitinib:激酶选择性、研究进展与实验应用全解析
已经有0人回复
矢车菊素-3-O-葡萄糖苷质控实录:从一张HPLC图谱读懂纯度与稳定性
已经有0人回复
恩诺沙星(Enrofloxacin)科研解析:分子特征、LC-MS/MS 检测与实验室使用要点
已经有0人回复
Calderasib理化性质与实验操作技术笔记
已经有0人回复
RMC-6291怎么用?RAS(ON) 三重复合物工具化合物的实验室实操要点
已经有0人回复
苯并呋咱全解析:NBD 荧光衍生化试剂母核的化学特性与实验室应用
已经有0人回复
生物质炭与活化剂氢氧化钾混合注意事项
已经有0人回复
晋鹏
版主 (知名作家)
- MolEPI: 6
- 应助: 626 (博士)
- 贵宾: 0.096
- 金币: 27592.6
- 散金: 1052
- 红花: 288
- 沙发: 2
- 帖子: 5663
- 在线: 726.4小时
- 虫号: 1183978
- 注册: 2011-01-05
- 性别: GG
- 专业: 生物信息学
- 管辖: 农林

2楼2017-10-07 20:42:16










回复此楼